Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Proteomics International Laboratories Ltd has reported a breakthrough in kidney health management for type 1 diabetes patients, revealing that its PromarkerD test accurately predicts renal decline with an AUC of 0.93. This expansion to type 1 diabetes builds upon the test’s prior validation in type 2 diabetes and taps into a new market given the global prevalence of diabetes. The findings are set to revolutionize early detection and intervention, potentially improving outcomes for millions of patients worldwide.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.
